Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial
Cudkowicz, Merit E, Prof, van den Berg, Leonard H, Prof, Shefner, Jeremy M, Prof, Mitsumoto, Hiroshi, Prof, Mora, Jesus S, MD, Ludolph, Albert, Prof, Hardiman, Orla, Prof, Bozik, Michael E, MD, Ingersoll, Evan W, PhD, Archibald, Donald, MPhil, Meyers, Adam L, MS, Dong, Yingwen, PhD, Farwell, Wildon R, MD, Kerr, Douglas A, MD
Published in Lancet neurology (01.11.2013)
Published in Lancet neurology (01.11.2013)
Get full text
Journal Article
The Combined Assessment of Function and Survival (CAFS): A new endpoint for ALS clinical trials
Berry, James D., Miller, Robert, Moore, Dan H., Cudkowicz, Merit E., Van Den Berg, Leonard H., Kerr, Douglas A., Dong, Yingwen, Ingersoll, Evan W., Archibald, Donald
Published in Amyotrophic lateral sclerosis and frontotemporal degeneration (01.04.2013)
Published in Amyotrophic lateral sclerosis and frontotemporal degeneration (01.04.2013)
Get full text
Journal Article
The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis
Cudkowicz, Merit, Bozik, Michael E, Ingersoll, Evan W, Miller, Robert, Mitsumoto, Hiroshi, Shefner, Jeremy, Moore, Dan H, Schoenfeld, David, Mather, James L, Archibald, Donald, Sullivan, Mary, Amburgey, Craig, Moritz, Juliet, Gribkoff, Valentin K
Published in Nature medicine (01.12.2011)
Published in Nature medicine (01.12.2011)
Get full text
Journal Article